By Reuters Staff
2 Min Read
WASHINGTON (Reuters) - The U.S. Federal Trade Commission said on Monday it has filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.
In addition to Endo Pharmaceuticals Inc and Impax Laboratories LLC, the lawsuit names as defendants Endo International Plc and Impax’s owner, Amneal Pharmaceuticals Inc, the agency said.
The U.S. Food and Drug Administration had asked Endo in June 2017 to pull its extended-release oxymorphone product off the market because of concerns that it was vulnerable to intravenous abuse, the FTC said.
Migraine with Brainstem Aura Market - Global Industry Analysis by Size, Share, Growth, Trends and Forecast till 2023
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Overactive Bladder Treatment Market to Expected to Register 3 1% CAGR, Says Market Research Future
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.